Research Briefings

Blossom has joined forces with Report on Psychedelics to produce a bi-weekly briefing on psychedelic research. Each briefing recaps the latest psychedelic research in easy to understand language. The briefings aim to help grow the impact of psychedelic research and accurately represent findings to a wider audience.

In the Research Briefing of January 10th: 1) Psilocybin can be administered safely for up to six people simultaneously 2) An Open Science approach toward MDMA synthesis 3) Nitrous Oxide could be the next antidepressant
In the Research Briefing of December 20th: 1) New double-blind study doesn't find benefits of microdosing 2) The negative post-acute effects of MDMA appear to be absent in the clinical setting
In the Research Briefing of December 6th: 1) The methodological challenges faced in psychedelic clinical trials (and how to fix them) 2) Mystical experiences in recreational use associated with improvements in wellbeing 3) A novel 5-MeO-DMT formulation proves to be safe in Phase I trial
In the Research Briefing of November 22nd: 1) Those who microdose report lower anxiety & depression 2) Psilocybin therapy increases cognitive and neural flexibility 3) How can psilocybin help decrease craving in alcoholism
In the Research Briefing of November 8th: 1) To patent or not to patent psychedelics 2) Getting psychedelics to a community clinic near you 3) The influence of cannabis on psychedelic experiences
In the Research Briefing of October 25th: 1) A summary of what we know about 5-MeO-DMT 2) Investigating ketamine's chemical structure for safety and efficacy 3) Testing how LSD works in the brain by modelling the effects in a whole-brain simulation
In the Research Briefing of October 11th 1) Good news for microdosing from a neuroimaging study 2) MDMA-assisted therapy could help those with with social anxiety disorder 3) Shamanistic practitioners show psychedelic-like brainwaves when drumming
In the Research Briefing of September 23rd 1) How ayahuasca ceremony leaders regard preparation and integration 2) Psychedelics for treating neurodegenerative disorders such as Alzheimer's 3) The relative safety of LSD in research settings
In the Research Briefing of August 27th: 1) The considerable risks of ibogaine 2) Psychiatrists favourable about psychedelics as medicines 3) Quitting tobacco addiction after psychedelic use
In the Research Briefing of July 23rd: 1) LSD increases empathy via oxytocin independent of serotonin receptor activity 2) Low dose LSD engenders therapeutic processes by inducing suggestibility alongside psychosis-like phenomena and mystical experiences 3) Novel gene repression method improves the yield of psilocybin biosynthesis by over 300%

Research Briefings

Blossom has joined forces with Report on Psychedelics to produce a bi-weekly briefing on psychedelic research. Each briefing recaps the latest psychedelic research in easy to understand language. The briefings help you make sense of the latest psychedelic research through explanation and adding context to research papers.

Recent briefings are also accompanied by an audio recording that is released on the podcast channel of Report on Psychedelics.

Understand the latest psychedelic research with our bi-weekly research briefing.

Become a psychedelic insider!

With a free Blossom membership you will always be in the know.

📰 Weekly newsletter about the psychedelic research

✔️ Unlimited access to our database and original articles

🖊️ Add (private) notes and comments to each page

Make an account